RxDoctor Payments Data

Kristen Lee

Nurse Practitioner · Spokane, WANPI 1871665299

Payments from drug & device makers

$3,200in general payments, 2019–2025

Across 147 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$313
  • Takeda Pharmaceuticals U.S.A., Inc.$284
  • Regeneron Healthcare Solutions, Inc.$243
  • Lilly USA, LLC$160
  • Bristol Myers Squibb$132
  • plus $630 from 15 others

What the payments were for

  • Food & beverage$3,10197%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,200 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$44,496
Medicare patients
314
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab47$540,076
Humira PenAdalimumab23$173,912
RinvoqUpadacitinib17$158,378
CreonLipase/Protease/Amylase31$110,786
Cimzia (2 Pack)Certolizumab Pegol12$81,170
LotronexAlosetron Hcl13$66,463
LinzessLinaclotide22$22,334
Mesalamine55$18,643
MotegrityPrucalopride Succinate22$16,545
TrulancePlecanatide11$14,448
Dexlansoprazole DrDexlansoprazole21$9,095
Colesevelam Hcl42$8,194
Omeprazole357$6,648
Famotidine300$5,617
Colestipol Hcl65$5,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Linzess$1,438$291,49870 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$284$16,54522 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$41$14,44811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →